Accro Bioscience

Accro Bioscience (Suzhou) Limited, trading as Accropeutics, is a clinical-stage biopharmaceutical company founded in 2017 with operations in Suzhou, China and New York. It develops small-molecule therapeutics against regulated cell death — necroptosis, pyroptosis and ferroptosis — targeting the cell-death-to-inflammation loop behind inflammatory, fibrotic, autoimmune and oncology disease. Its pipeline is led by AC-101, an oral selective RIPK2 inhibitor in Phase Ib for ulcerative colitis with FDA clearance for a Phase II multi-regional IBD study; AC-201, a TYK2/JAK1 pseudokinase inhibitor licensed to Fosun Pharma for Greater China as FXS5626; and AC-003, a RIPK1 inhibitor in Phase Ib for acute graft-versus-host disease with FDA Orphan Drug Designation. It closed a $50M Series C led by OrbiMed in May 2026. Accro Bioscience sells drug candidates, not software: it runs no developer program and publishes no API, SDK or machine-readable API contract.

Accro Bioscience is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Discovery, and Clinical Trials.

🌐 Visit website 📡 Source on GitHub

3.3/100 minimal Agent 0/100 human only Full breakdown ↓
scored 2026-09-06 · rubric v0.19.0

0 APIs

Company Biotechnology Pharmaceuticals Drug Discovery Clinical Trials Life Sciences ImmunologyInflammationSmall MoleculeRegulated Cell Death

Kin Score

Kin Score How this is scored →
scored 2026-09-06 · rubric v0.19.0

Composite quality — 3.3/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Delegated User Identity 0 / 6

Protected Resource Metadata 0 / 5

Registration Without a Human 0 / 6

Agentic Commerce Well-Known Document 0 / 5

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/accrobioscience: open an issue to ask a question, or submit a pull request to add artifacts. Submit an artifact on GitHub — free → Manage your own listing — the Influence plan, $499/mo →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Company 6

The organization behind the API

Website

About

Newsroom

Partners

Careers

LinkedIn

Other 1

Properties that don't map to a standard resource type

SecondaryMarket

SecondaryMarket

Source (apis.yml)

aid: accrobioscience
name: Accro Bioscience
description: 'Accro Bioscience (Suzhou) Limited, trading as Accropeutics, is a clinical-stage biopharmaceutical company founded
  in 2017 with operations in Suzhou, China and New York. It develops small-molecule therapeutics against regulated cell death
  — necroptosis, pyroptosis and ferroptosis — targeting the cell-death-to-inflammation loop behind inflammatory, fibrotic,
  autoimmune and oncology disease. Its pipeline is led by AC-101, an oral selective RIPK2 inhibitor in Phase Ib for ulcerative
  colitis with FDA clearance for a Phase II multi-regional IBD study; AC-201, a TYK2/JAK1 pseudokinase inhibitor licensed
  to Fosun Pharma for Greater China as FXS5626; and AC-003, a RIPK1 inhibitor in Phase Ib for acute graft-versus-host disease
  with FDA Orphan Drug Designation. It closed a $50M Series C led by OrbiMed in May 2026. Accro Bioscience sells drug candidates,
  not software: it runs no developer program and publishes no API, SDK or machine-readable API contract.'
url: https://raw.githubusercontent.com/api-evangelist/accrobioscience/refs/heads/main/apis.yml
image: https://www.accropeutics.com/upload/2024-05/171677317462138100.svg
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-09-06'
modified: '2026-09-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Clinical Trials
- Life Sciences
- Immunology
- Inflammation
- Small Molecule
- Regulated Cell Death
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/accrobioscience-domain-security.yml
- type: Website
  url: https://www.accropeutics.com/
- type: About
  url: https://www.accropeutics.com/about
- type: Newsroom
  url: https://www.accropeutics.com/news
- type: Contact
  url: https://www.accropeutics.com/contact
- type: Partners
  url: https://www.accropeutics.com/partnerships
- type: Careers
  url: https://www.accropeutics.com/join
- type: LinkedIn
  url: https://www.linkedin.com/company/95295041/
- type: SecondaryMarket
  url: https://equityzen.com/company/accrobioscience
x-enrichment:
  date: '2026-09-06'
  status: minimal
  artifacts_added: 2
  pass: local-v3
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Accro Bioscience (Suzhou) Limited is a clinical-stage biopharmaceutical company whose product is a small-molecule
    drug pipeline (AC-101, AC-201, AC-003), not software; its entire public surface is the accropeutics.com corporate site
    — about, focus areas, pipeline, partnerships, news, join us, contact — with no developer, docs, portal or integration
    link anywhere in the nav or footer, and the site does not even serve a /robots.txt or /sitemap.xml. Every REST/GraphQL/agent-card,
    /llms.txt and /.well-known/ path probed on both www.accropeutics.com and accropeutics.com returns an identical 548-byte
    hard 404, verified against a random control path returning the same body and byte count; api., dev., docs., developer.,
    portal., data. and mcp..accropeutics.com do not resolve in DNS, and there is no GitHub organization and no npm or PyPI
    package under either the Accro Bioscience or Accropeutics name.
  evidence:
  - url: https://www.accropeutics.com/
    status: 200
  - url: https://www.accropeutics.com/openapi.json
    status: 404
  - url: https://www.accropeutics.com/swagger.json
    status: 404
  - url: https://www.accropeutics.com/api-docs
    status: 404
  - url: https://www.accropeutics.com/graphql
    status: 404
  - url: https://www.accropeutics.com/developers
    status: 404
  - url: https://www.accropeutics.com/llms.txt
    status: 404
  - url: https://www.accropeutics.com/robots.txt
    status: 404
  - url: https://www.accropeutics.com/.well-known/agent-card.json
    status: 404
  - url: https://www.accropeutics.com/.well-known/agent.json
    status: 404
  - url: https://www.accropeutics.com/.well-known/api-catalog
    status: 404
  - url: https://accropeutics.com/.well-known/security.txt
    status: 404
  - url: https://www.accropeutics.com/zz-api-evangelist-control-7c1e
    status: 404
  - url: https://api.github.com/search/users?q=accro+bioscience
    status: 200
  checked: '2026-09-06'

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this

find_providersBrowse and filter every provider in the catalog.
get_provider_artifactsEvery artifact this provider publishes, grouped by type.
get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
get_provider_ratingPRO — composite, band, trend and facet scores.
apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
resolveTurn a domain, URL or GitHub org into the provider it belongs to.
find_cohortsEvery scored population of providers in the catalog.

All 92 tools →

Call it yourself

curl for this page

This provider

curl "https://apis.io/api/v1/providers/accrobioscience"

All providers

curl "https://apis.io/api/v1/providers?limit=25"

Every operation they expose

curl "https://apis.io/api/v1/providers/accrobioscience/operations?limit=25"

How their score was established

curl "https://apis.io/api/v1/providers/accrobioscience/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no email required.

GitHub Google LinkedIn

A second provider on the same verified email joins the account you already have.